Blood Testing Market Size & Growth Forecast 2027–2036, By Segments (Method, Product, End-use, Test Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to content
Market Size and Growth Outlook
Blood Testing Market size was worth USD 91.96 Billion in 2026 and is expected to grow at 7.84% CAGR between 2027 and 2036, attaining USD 195.61 Billion by 2036. The industry revenue for 2027 is calculated at USD 98.08 Billion.
Get more details on this report
Request Free Sample ReportBlood Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America leads through advanced diagnostic infrastructure, high laboratory utilization, and strong demand for early detection, routine screening, and chronic disease monitoring.
- Asia Pacific is growing fastest as healthcare infrastructure, laboratory capabilities, preventive diagnostics, and access to blood testing services expand.
Segment Momentum
- Automated testing held a 68.45% market share in 2026 and is the fastest-growing method because it delivers high-throughput processing, greater analytical accuracy, standardized results, and improved laboratory efficiency.
- Instruments are the fastest-growing product segment as healthcare facilities invest in advanced analyzers and integrated diagnostic platforms to improve testing precision, increase throughput, and support expanding laboratory automation.
Market Expansion Drivers
- Growing chronic disease burden driving routine diagnostic blood testing demand globally
- Expansion of point-of-care testing centers improving decentralized diagnostic accessibility
- Increasing healthcare expenditure enabling adoption of advanced automated blood testing platforms
Leading Market Participants
- Major players in the blood testing market include F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (United States), Siemens Healthineers AG (Germany), Danaher Corporation (United States), Becton, Dickinson and Company (United States), bioMérieux SA (France), Thermo Fisher Scientific Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Grifols S.A. (Spain), Sysmex Corporation (Japan)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 91.96 Billion
- 2027 Estimated Market Size: USD 98.08 Billion
- Projected Market Size: USD 195.61 Billion by 2036
- Growth Forecast: 7.84% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Automated (Method) | Reagents & Kits (Product) | Hospitals (End-use) | Complete Blood Count (CBC) (Test Type)
- Emerging Opportunity Segment: Automated (Method) | Instruments (Product) | Hospitals (End-use) | Infectious Disease Blood Tests (Test Type)
Market Growth Drivers and Industry Trends
Growing chronic disease burden driving routine diagnostic blood testing demand globally
The rising prevalence of chronic illnesses has made regular laboratory monitoring an essential component of long-term patient care, and this trend will propel the blood testing market growth across healthcare systems. Blood tests are routinely used to detect diseases, monitor treatment response, evaluate organ function, and identify complications before symptoms worsen. As healthcare providers place greater emphasis on early diagnosis and continuous disease management, demand for reliable and repeat diagnostic testing continues to expand across hospitals, diagnostic laboratories, and outpatient care settings.
Expansion of point-of-care testing centers improving decentralized diagnostic accessibility
Improved access to decentralized healthcare services is transforming diagnostic delivery, with the blood testing market gaining momentum as point-of-care testing centers become more widely available. These facilities enable faster clinical decision-making by providing timely test results closer to patients, reducing dependence on centralized laboratories and shortening turnaround times. Their growing presence supports healthcare delivery in community clinics, emergency care environments, and underserved regions where immediate diagnostic information is critical for effective patient management.
Increasing healthcare expenditure enabling adoption of advanced automated blood testing platforms
Higher investment in healthcare infrastructure is encouraging laboratories and medical institutions to modernize diagnostic capabilities, which will boost the blood testing market demand for automated testing platforms. Advanced laboratory systems improve workflow efficiency, reduce manual intervention, and enhance consistency in sample processing while supporting higher testing volumes. Healthcare providers are increasingly adopting automation to strengthen diagnostic accuracy, optimize laboratory operations, and address growing demand for routine as well as specialized blood analyses.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing chronic disease burden driving routine diagnostic blood testing demand globally | 2% | High | North America, Europe | High | Near Term |
| Expansion of point-of-care testing centers improving decentralized diagnostic accessibility | 1.8% | High | Asia Pacific, North America | High | Mid Term |
| Increasing healthcare expenditure enabling adoption of advanced automated blood testing platforms | 1.6% | High | Europe, North America | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the blood testing market, North America held the largest share in 2026, supported by advanced diagnostic infrastructure, high utilization of laboratory services, and strong demand for early disease detection and routine health screening. The region's well-established healthcare systems facilitate widespread use of blood-based diagnostics across hospitals, clinics, laboratories, and preventive healthcare programs. Increasing emphasis on monitoring chronic conditions, personalized treatment decisions, and timely diagnosis is also contributing to sustained demand for comprehensive blood testing services and technologies.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is anticipated to register the fastest growth, fueled by expanding healthcare infrastructure, increasing awareness of preventive diagnostics, and rising demand for accessible testing services. Improvements in laboratory capabilities and healthcare delivery are enabling broader adoption of blood testing across both urban and developing healthcare markets. The growing prevalence of chronic diseases, increasing focus on early detection, and expansion of diagnostic services are encouraging healthcare providers to strengthen testing capacity, while technological advances are helping improve the accessibility and efficiency of blood-based diagnostics.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Precision Diagnostics AdoptionThe U.S. blood testing market emphasizes advanced diagnostic platforms, preventive screening, and integration with digital healthcare systems. Laboratories and healthcare providers continue expanding high-value testing services that improve clinical decision-making and operational efficiency.
Germany 🇩🇪
Laboratory Quality FocusGermany prioritizes standardized laboratory workflows and high-accuracy blood testing supported by strong clinical quality requirements. Healthcare institutions increasingly adopt automated testing technologies that enhance consistency while addressing growing diagnostic demand.
Japan 🇯🇵
Preventive Healthcare IntegrationJapan continues strengthening blood testing through preventive healthcare programs and routine health examinations. Clinical laboratories focus on efficient testing processes and reliable diagnostic performance to support an aging population and long-term disease management.
South Korea 🇰🇷
Digital Laboratory ExpansionSouth Korea advances blood testing through digitally connected laboratories and modern diagnostic infrastructure. Healthcare providers increasingly implement automated testing solutions that improve turnaround times and support broader access to precision diagnostics.
France 🇫🇷
Clinical Screening EnhancementFrance continues expanding blood testing within preventive care and hospital-based diagnostics. The country prioritizes reliable laboratory services and efficient testing workflows to strengthen disease detection and improve patient management across healthcare settings.
Italy 🇮🇹
Hospital Testing ModernizationItaly focuses on modernizing hospital laboratories and expanding access to accurate blood testing services. Investments in automation and workflow optimization support improved diagnostic efficiency while meeting growing demand for routine and specialized testing.
Blood Testing Market Share (%), by Method, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportMethod Segment Analysis: Automated (Largest & Fastest-Growing Segment)
The blood testing market was dominated by the automated method segment, which accounted for 68.45% in 2026 while also emerging as the fastest-growing segment. Automated testing systems are widely adopted because they deliver high-throughput processing, improved analytical accuracy, and standardized results while minimizing manual intervention and the risk of human error. Healthcare providers and diagnostic laboratories increasingly rely on automation to handle growing testing volumes, reduce turnaround times, and optimize laboratory workflows. Continued advancements in laboratory automation, integration with digital information systems, and demand for efficient diagnostic services are expected to reinforce the segment’s leadership.
Product Segment Analysis: Reagents & Kits (Largest Segment) vs Instruments (Fastest-Growing Segment)
The reagents & kits segment held the largest share of 62.33% in 2026, supported by their recurring use across routine diagnostics, disease screening, and specialized blood analyses. Since reagents and kits are consumed with every test performed, they generate sustained demand from hospitals, diagnostic laboratories, and blood banks. Ongoing expansion of preventive healthcare programs and increasing utilization of laboratory testing continue to strengthen the segment's dominant position.
The blood testing market is witnessing the fastest expansion in the instruments segment as healthcare facilities continue investing in advanced analyzers and integrated diagnostic platforms. Modern instruments improve testing efficiency, enhance analytical precision, and support higher sample throughput, enabling laboratories to meet rising diagnostic demands. Continuous technological innovation and the growing need for automated laboratory infrastructure are expected to accelerate adoption of advanced blood testing instruments.
End-use Segment Analysis: Hospitals (Largest & Fastest-Growing Segment)
Hospitals represented the largest end-use segment, capturing 50.03% in 2026, while also registering the fastest growth in the blood testing market. Hospitals conduct a broad range of diagnostic tests for emergency care, inpatient treatment, surgical procedures, chronic disease management, and routine health assessments, creating consistent demand for blood testing services. Their comprehensive laboratory capabilities, access to advanced diagnostic technologies, and increasing patient admissions support sustained utilization of blood testing solutions. Growing emphasis on early disease detection and integrated clinical diagnostics further reinforces hospitals' leading position within the market.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Method | Automated, Manual | Automated | Automated |
| Product | Reagents & Kits, Instruments, Software | Reagents & Kits | Instruments |
| End-use | Hospitals, Pathology Labs, Blood Banks, Diagnostic Centers, Others | Hospitals | Hospitals |
| Test Type | Complete Blood Count (CBC), Blood Glucose Tests, Lipid Profile Tests, Renal Function Tests, Liver Function Tests, Infectious Disease Blood Tests, Cardiac Biomarker Tests, Cancer Biomarker Tests, Immunological/Autoimmune Blood Tests, Coagulation Tests, Others | Complete Blood Count (CBC) | Infectious Disease Blood Tests |
Competitive Landscape and Market Positioning
Leading companies in the blood testing market:
- F. Hoffmann-La Roche AG (Switzerland)
- Abbott Laboratories (United States)
- Siemens Healthineers AG (Germany)
- Danaher Corporation (United States)
- Becton Dickinson and Company (United States)
- bioMérieux SA (France)
- Thermo Fisher Scientific, Inc. (United States)
- Bio-Rad Laboratories, Inc. (United States)
- Grifols S.A. (Spain)
- Sysmex Corporation (Japan)
Advances in diagnostic science are redefining competition as laboratories, testing service providers, and technology developers seek to deliver broader clinical insights from increasingly efficient testing workflows. Market participants are expanding beyond routine diagnostics by integrating molecular techniques, automation, and digital interpretation capabilities that improve clinical decision-making while supporting faster turnaround times. At the same time, the ability to address preventive healthcare, chronic disease management, and decentralized testing environments is becoming an important differentiator, encouraging continuous refinement of testing platforms, laboratory integration, and service quality across diverse healthcare settings.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche AG (Switzerland) | |||||||
| Abbott Laboratories (United States) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Grifols S.A. (Spain) | |||||||
| Sysmex Corporation (Japan) |
Industry Development / News
| Company Name | Date | Key Development |
|---|---|---|
| Truvian | Dec-25 | Truvian achieved FDA clearance for its benchtop blood-testing system. This regulatory milestone is a critical step for the company's commercial scalability, setting the stage for a broader market rollout as it continues to pursue additional clearances for its comprehensive blood panel diagnostic menu. |
| Abbott | Nov-25 | Abbott acquired Exact Sciences for $21 billion, a major consolidation move positioning Abbott as a leader in cancer diagnostics. The transaction integrates Exact Sciences' portfolio, including the Cancerguard multi-cancer early detection blood test, significantly expanding Abbott's operational footprint and competitive capabilities in advanced molecular oncology and liquid biopsy screening. |
| Roche | Nov-25 | Roche executed a $200 million licensing agreement and a $75 million equity investment in Freenome. This strategic partnership focuses on developing and commercializing blood-based cancer screening tests outside the U.S., signaling a major expansion effort for Roche’s oncology diagnostic portfolio through high-value external technology integration. |
| Sonic Healthcare USA | Nov-25 | Sonic Healthcare USA acquired Cairo Diagnostics while simultaneously relocating its U.S. headquarters to Dallas. This dual action enhances the company's regional operational infrastructure and expands its diagnostic service capacity, specifically strengthening its portfolio in advanced cancer-related blood testing and diagnostic support services. |
| Function Health | May-25 | Function Health acquired full-body MRI company Ezra, significantly broadening its preventive health diagnostic offerings. By integrating advanced imaging services with its existing blood testing platform, the company is positioning itself to capture a larger share of the integrated consumer health monitoring market. |
| BD | Jan-25 | BD expanded its strategic collaboration with Babson Diagnostics to deploy fingertip blood collection technology across urgent care and physician office networks. This initiative represents a material shift in point-of-care operations, enhancing clinical access to minimally invasive blood testing in decentralized settings. |
| QIAGEN | Sep-24 | QIAGEN launched a new digital PCR system specifically designed for oncology clinical testing. The system enables high-precision DNA and RNA quantification, enhancing the technical capabilities for liquid biopsy and cancer monitoring, which are central to the evolution of the clinical blood diagnostics market. |
| Werfen | Jul-24 | Werfen introduced the GEM Premier 7000 with iQM3, the first point-of-care blood gas testing system featuring integrated hemolysis detection. This launch represents a material technological upgrade in critical care diagnostics, providing improved accuracy and operational efficiency in high-acuity blood analysis settings. |
| Abbott | Apr-24 | Abbott secured FDA clearance for its i-STAT TBI whole blood rapid test cartridge, developed in collaboration with the U.S. Army. This innovation significantly advances point-of-care diagnostic capabilities for traumatic brain injury, demonstrating the commercialization of new, high-utility blood-based testing technologies in critical care environments. |
| Veracyte | Jan-24 | Veracyte acquired C2i Genomics in a deal valued at up to $95 million. This acquisition bolsters Veracyte’s genomic testing capabilities and strengthens its competitive positioning in the blood-based cancer diagnostics segment by integrating specialized liquid biopsy and molecular monitoring technologies into its commercial product portfolio. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Blood Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Population | Adult, Pediatric, Geriatric, Neonatal |
| Sample Type | Whole Blood, Plasma, Serum, Capillary Blood |
| Testing Setting | Central Laboratories, Hospital Laboratories, Physician Office Laboratories, Point-of-Care Settings |
Blood Testing Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Diagnostic Testing Pathway Optimization |
|
| Centralized vs Decentralized Testing Models |
|
| Laboratory Automation Adoption |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How big is the blood testing market?
How will the blood testing industry grow in terms of size and CAGR by 2036?
How is decentralized healthcare influencing the blood testing market?
Why are healthcare providers investing in automated blood testing platforms?
Why is the automated method the leading segment in the blood testing market?
What is driving the rapid growth of blood testing instruments?
Why does North America hold the largest share of the blood testing market?
How is Asia Pacific accelerating blood testing market growth?
Who are the major participants shaping the blood testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook